Let’s start with a
patient case. An elderly patient with
multiple comorbidities is being treated in the hospital for heart failure when
he develops an acute gouty attack. His past
medical history, among other things, includes CKD (Stage 4). Should colchicine be used in this patient and
if so, what dose would be indicated?
The American College of
Rheumatology guidelines for the treatment of acute gout consider colchicine,
NSAIDs, and corticosteroids all first
line monotherapy (Evidence A) for moderate severity pain in 1-2
joints. A combination of these is
appropriate to consider in severe pain (Evidence C). Since all have the same grade evidence for
first line therapy, agent selection should be based on prior response,
comorbidities, and patient preference while also considering each agent’s drug
interactions.
Colchicine is a viable
option for gout attacks that have begun within
36 hours (Evidence C). In the recent
past, typical dosing for colchicine included a 1.2mg loading dose, followed by
0.6mg every one to two hours as needed for pain or until gastrointestinal
intolerance was met. This is not the current dose recommended by the
ACR or FDA. New dosing came about with
FDA approval of colchicine (Colcrys) in 2009 specifying a dose of 1.2mg orally
once, followed by 0.6mg one hour later, not to be repeated for two weeks in
those with severe renal dysfunction.
This change was largely the results of the first multicentered,
randomized, double-blind, placebo-controlled, dose-comparison study of
colchicine1.
*Results of their dose
comparison is displayed in the graph above– “low dose” refers to the 1.8mg
maximum described above and “high dose” refers to a six hour dosing strategy
like that described further above, up to a maximum of 4.8mg. Note that efficacy is similar. Adverse events were significantly less in the
low-dose group.
Back to the patient case:
- Colchicine is a viable option if started within 36 hours on onset of acute gout
- A dosing strategy of 1.2mg orally once, then 0.6mg in one hour is recommended
- No renal adjustment needs to be made but the colchicine course should not be repeated for two weeks
Background:
Colchicine, in the form
of plant extracts (colchicum autumnale shown above), has been used for the treatment of acute gout for over 2000
years and a relatively pure form of
colchicine has been isolated and in use since 1883. By the time the FDA began requiring that all
new drugs demonstrate safety in 1938 and efficacy in 1962, colchicine did not
need to meet these requirements and was “grandfathered” into the market. Due to this unapproved/grandfathered status
and the fact that the generic colchicine was manufactured by several different
companies, there was little incentive (read: no company stood to make money) to
ever perform a dose-finding study prior to 2006.
Prior to 2010, there
was only one randomized
placebo-controlled study examining the use of colchicine in gout and it
included ~40 patients2. As
part of the FDA’s Unapproved Drug Initiative in 2006, URL Pharma supported the
study whose graph is shown above1 and applied for a brand name
version “Colcrys” for the treatment of acute gout. The application was approved, increasing the
cost of colchicine from generic (pennies/tablet) to brand ($4-5/tablet).
Colchicine is
transported by p-glycoprotein, is metabolized by CYP3A4, and is eliminated
renally and in the bile. If scheduled
dosing is used for any indication, renal adjustment and drug interactions need
to be taken into account and dosage adjustments made.
Take home point:
- Look in the prescribing information, Lexicomp, or Micromedex when dosing this drug and checking for interactions
References:
1. Terkeltaub RA,
Furst DE, Bennett K, Kook KA, Crockett RS, Davis MW, et al. High versus low dosing
of oral colchicine for early acute gout flare: twenty-four–hour outcome of the
first multicenter, randomized, double-blind, placebo-controlled,
parallel-group, dose-comparison colchicine study. Arthritis Rheum
2010;62:1060–8.
2. Ahern MJ, Reid C, Gordon TP, McCredie M,
Brooks PM, Jones M. Does colchicine work? The results of the first controlled
study in acute gout. Aust NZ J Med 1987;17:301-4.
photo by AnyMotion
photo by AnyMotion
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.